¡Ya estamos en ! Descubre más

Brainsway

BWAY

Capitalización de mercado USD 460 M

11.44 USD

-0.38

3.21%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

1 día

-3.21%

5 días

-1.04%

1 mes

-15.01%

3 meses

-22.91%

6 meses

-25.38%

En lo que va del año

18.55%

1 año

43%

5 años

190.36%

10 años

106.13%

Acerca de: BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Empleados: 129

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 45.5%

Neutral 54.5%

Negativo 0%

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol.

BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™

Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™

Zacks Investment Research

Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?

The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?

Zacks Investment Research

Brainsway (BWAY) Upgraded to Buy: Here's Why

Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Brainsway (BWAY) Upgraded to Buy: Here's Why

Brainsway Q2 Earnings Call Highlights

Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.

Brainsway Q2 Earnings Call Highlights

BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem

BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for interventional psychiatry, leveraging recurring revenue and minority investments. BWAY reported Q1-2026 revenue up 35% YoY, a steady 75% gross margin, and expects FY-2026 revenue of $66–68M with adjusted EBITDA growth of 86–100%. Multi-year leasing, accelerated protocols, and expanded provider access are reducing TMS adoption barriers, supporting higher utilization and stickier customer relationships.

BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem

Zacks Investment Research

Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable

Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable

Zacks Investment Research

4 Medical Products Stocks Poised to Win Despite Industry Headwinds

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.

4 Medical Products Stocks Poised to Win Despite Industry Headwinds

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™